← Holdings
TEVA

Teva Pharmaceutical

2 managers · $687M total
Data: SEC EDGAR 13F · 2026Q2
Manager holders · last 5 qtrsⓘ
1
2025Q2 – 2026Q2 · flat QoQ
Total position
$687M
Combined value across tracked managers
Net move this quarter
↓ Trimming
Weighted by holders' share change
HolderQ actionValue% of port.Style
LingottoTrim-27.24%$685M14.67%High-conviction growth / Innovation-led
GreenlightNew$3M0.14%Value / Long-short
What managers sayⓘ
2026-07-27Cobas Asset ManagementBearComment First Semester 2026Detail →
2025-01-31Cobas Asset ManagementBullComment Second Semester 2024Detail →
2025-01-14Colossus (Invest Like the Best / Business Breakdowns)NeutralTal Zaks - Bridging Science, Medicine, and Returns - [Invest Like the Best, EP.406]Detail →
2024-07-23Cobas Asset ManagementNeutralComment First Semester 2024Detail →
2023-07-27Cobas Asset ManagementNeutralComments on First Semester 2023Detail →
2023-07-21Patient Capital ManagementNeutral2Q23 Opportunity Equity Portfolio Activity and AttributionDetail →
2023-02-02Cobas Asset ManagementBullComments on Fourth Quarter 2022Detail →
2022-07-27Cobas Asset ManagementNeutralComments on Second Quarter 2022Detail →
Earnings Callsⓘ

No earnings call data yet

FinancialsⓘFY2025 · Source: SEC EDGAR 10-K

5y revenue CAGR 2% · latest net margin 8.2% · FCF consistently positive

Revenue$17.3B
Rev. YoY+4.3%
Gross margin51.8%
Net margin8.2%
Net income$1.41B
Free cash flow$1.15B
Operating cash flow$1.65B
ROE17.8%

Source: SEC EDGAR company filings (10-K). Foreign issuers (20-F/IFRS) not yet covered.